These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 18176117

  • 1. Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
    Recchia F, Candeloro G, Necozione S, Fumagalli L, Bratta M, Rea S.
    Anticancer Drugs; 2008 Feb; 19(2):201-7. PubMed ID: 18176117
    [Abstract] [Full Text] [Related]

  • 2. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS.
    J Clin Oncol; 2009 Dec 20; 27(36):6207-12. PubMed ID: 19917850
    [Abstract] [Full Text] [Related]

  • 3. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
    Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N.
    Cancer J Sci Am; 1997 Dec 20; 3 Suppl 1():S9-15. PubMed ID: 9457387
    [Abstract] [Full Text] [Related]

  • 4. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
    O'Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HJ, Martin M, Deck R, Ames P, Shinn K, Kim H, Fournier P, Gammon G.
    Clin Cancer Res; 2002 Sep 20; 8(9):2775-81. PubMed ID: 12231516
    [Abstract] [Full Text] [Related]

  • 5. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulos N.
    Ann Oncol; 1996 Oct 20; 7(8):827-35. PubMed ID: 8922197
    [Abstract] [Full Text] [Related]

  • 6. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.
    Clin Cancer Res; 2000 Jun 20; 6(6):2201-8. PubMed ID: 10873069
    [Abstract] [Full Text] [Related]

  • 7. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
    Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW.
    Clin Cancer Res; 2002 Oct 20; 8(10):3075-81. PubMed ID: 12374674
    [Abstract] [Full Text] [Related]

  • 8. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
    Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS.
    J Clin Oncol; 2007 Sep 01; 25(25):3802-7. PubMed ID: 17761969
    [Abstract] [Full Text] [Related]

  • 9. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
    González Cao M, Malvehy J, Martí R, Conill C, Sánchez M, Martín M, Carrera C, Herrero J, Gascón P, Mellado B, Castel T, Puig S.
    Melanoma Res; 2006 Feb 01; 16(1):59-64. PubMed ID: 16432457
    [Abstract] [Full Text] [Related]

  • 10. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO, Soori G, Wiemann MC, Schulof R, Dobbs TW, Ruben RH, DePriest CB, Church C.
    Cancer Biother Radiopharm; 2000 Oct 01; 15(5):487-94. PubMed ID: 11155820
    [Abstract] [Full Text] [Related]

  • 11. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
    Thompson JA, Gold PJ, Markowitz DR, Byrd DR, Lindgren CG, Fefer A.
    Cancer J Sci Am; 1997 Dec 01; 3 Suppl 1():S29-34. PubMed ID: 9457390
    [Abstract] [Full Text] [Related]

  • 12. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
    Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS.
    J Clin Oncol; 2002 Apr 15; 20(8):2045-52. PubMed ID: 11956264
    [Abstract] [Full Text] [Related]

  • 13. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH, Atzpodien J, Poliwoda H.
    Med Klin (Munich); 1996 Apr 12; 91 Suppl 3():44-9. PubMed ID: 8692119
    [Abstract] [Full Text] [Related]

  • 14. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
    Punt CJ, Suciu S, Gore MA, Koller J, Kruit WH, Thomas J, Patel P, Lienard D, Eggermont AM, Keilholz U.
    Eur J Cancer; 2006 Nov 12; 42(17):2991-5. PubMed ID: 17023156
    [Abstract] [Full Text] [Related]

  • 15. Combined chemoimmunotherapy of metastatic melanoma: a single institution experience.
    Di Lauro V, Scalone S, La Mura N, Zanetti M, Nigri P, Freschi A, Veronesi A.
    Melanoma Res; 2005 Jun 12; 15(3):209-12. PubMed ID: 15917704
    [Abstract] [Full Text] [Related]

  • 16. A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
    Minor DR, Madland MT, Kashani-Sabet M, Denny SR, Harvey WB.
    Cancer Biother Radiopharm; 2005 Oct 12; 20(5):479-86. PubMed ID: 16248763
    [Abstract] [Full Text] [Related]

  • 17. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
    Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, Dutcher J, Gordon MS, Lotze M, Mier J, Sorokin P, Fisher RI, Appel C, Du W.
    J Clin Oncol; 2001 Jul 01; 19(13):3194-202. PubMed ID: 11432886
    [Abstract] [Full Text] [Related]

  • 18. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R.
    Cancer; 2002 Jan 15; 94(2):470-6. PubMed ID: 11900232
    [Abstract] [Full Text] [Related]

  • 19. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
    Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N.
    J Clin Oncol; 1998 May 15; 16(5):1752-9. PubMed ID: 9586888
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
    Hess V, Herrmann R, Veelken H, Schwabe M.
    Oncology; 2007 May 15; 73(1-2):33-40. PubMed ID: 18332650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.